Analyst Price Targets — ARCT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 12:52 pm | Yasmeen Rahimi | Piper Sandler | $25.00 | $7.42 | StreetInsider | '2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler |
| January 22, 2026 9:08 pm | — | Roth Capital | $20.00 | $7.59 | TheFly | Arcturus Therapeutics initiated with a Buy at Roth Capital |
| August 22, 2025 11:45 am | Lili Nsongo | Leerink Partners | $54.00 | $18.51 | TheFly | Arcturus Therapeutics price target lowered to $54 from $63 at Leerink |
| May 28, 2025 11:11 am | Greg Harrison | Scotiabank | $32.00 | $11.82 | TheFly | Arcturus Therapeutics initiated with an Outperform at Scotiabank |
| March 10, 2025 9:14 am | Thomas Shrader | BTIG | $48.00 | $14.55 | StreetInsider | BTIG Reiterates Buy Rating on Arcturus Therapeutics (ARCT) |
| November 11, 2024 12:11 pm | Whitney Ijem | Canaccord Genuity | $10.58 | $3.02 | StreetInsider | Arcturus Therapeutics (ARCT) PT Raised to $74 at Canaccord Genuity |
| August 6, 2024 8:27 am | Whitney Ijem | Canaccord Genuity | $10.30 | $3.20 | TheFly | Arcturus Therapeutics price target lowered to $72 from $86 at Canaccord |
| July 2, 2024 6:38 am | Ed Arce | H.C. Wainwright | $8.58 | $3.38 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT) |
| May 31, 2024 7:40 am | Yasmeen Rahimi | Piper Sandler | $20.02 | $5.64 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Arcturus Therapeutics (ARCT) |
| May 10, 2024 7:24 am | Whitney Ijem | Canaccord Genuity | $12.30 | $3.83 | TheFly | Arcturus Therapeutics price target lowered to $86 from $87 at Canaccord |
Latest News for ARCT
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the company's investigational messenger RNA therapy for cystic fibrosis.
Arcturus Therapeutics Holdings Inc. (âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032,…
The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all of human history, according to one study.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARCT.
U.S. House Trading
No House trades found for ARCT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.